Monday, July 09, 2012 9:54:15 PM
Their goal is not to sell. I have seen this as a tactic to pick up shares on the other end. They try to make it look like there are big sells. They usually pull these and are never filled.
Recent ACAD News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/27/2026 12:00:15 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/27/2026 12:00:12 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/27/2026 12:00:12 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/27/2026 12:00:08 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/27/2026 12:00:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/20/2026 10:01:17 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/20/2026 10:00:14 PM
- Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum • Business Wire • 03/12/2026 08:05:00 PM
- Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors • Business Wire • 03/03/2026 09:05:00 PM
- Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome • Business Wire • 03/02/2026 09:05:00 PM
- Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 02/26/2026 11:59:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 09:20:21 PM
- Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operating Overview • Business Wire • 02/25/2026 09:05:00 PM
- Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences • Business Wire • 02/23/2026 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/10/2026 11:00:04 PM
- Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026 • Business Wire • 02/04/2026 09:05:00 PM
- Acadia Pharmaceuticals Provides Update on Regulatory Submission for Trofinetide for the Treatment of Rett Syndrome in the European Union • Business Wire • 02/02/2026 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/13/2026 08:58:51 PM
- Acadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference • Business Wire • 01/13/2026 02:00:00 PM
- Acadia Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 • Business Wire • 12/18/2025 09:05:00 PM
- Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome • Business Wire • 12/12/2025 01:00:00 PM
- Acadia Pharmaceuticals to Participate in Citi’s 2025 Global Healthcare Conference • Business Wire • 11/20/2025 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/19/2025 11:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/19/2025 11:00:05 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 11/14/2025 01:16:54 PM
